It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma

J Clin Oncol. 2017 Feb;35(4):475-477. doi: 10.1200/JCO.2016.69.7276. Epub 2016 Oct 28.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adenocarcinoma*
  • Cetuximab
  • Epirubicin
  • Esophageal Neoplasms*
  • Esophagogastric Junction
  • Humans
  • Stomach Neoplasms*

Substances

  • Epirubicin
  • Cetuximab